Breaking News on Contract Research, Manufacturing & Clinical Trials

New CRO in Hong Kong to feed China

By Kirsty Barnes, 21-Nov-2006

Related topics: Phase I-II, Phase III-IV, Clinical Development

A new contract research organization (CRO) has opened in Hong Kong and will be the only clinical trial site outside of China with the approval of China's State Food and Drug Administration (SFDA) to run oncology trials.

The new CRO, Bridgetech Medical Technologies Research (BMTR) is part of a new venture between US firm Bridgetech Holdings International and the Chinese University of Hong Kong.

 

Playing a part in the decision to open a CRO in the region was the fact that Hong Kong plays a strategically important role in China's healthcare development, according to Pro-vice-chancellor of the Chinese University Kenneth Young.

 

 

 

In addition to running clinical trials the site will also help facilitate regulatory approval from the Chinese regulatory authorities, as well as the US Food and Drug Administration (FDA).

 

 

 

The life science market in China is one of the fastest growing markets in the world and demand for contract services continues to escalate as the domestic pharma market continues to mature and many of the world's top pharma companies also begin to set up low-cost manufacturing operations in and around the country.

 

 

 

Asia, led by China, has the largest pool of patients with cancer, cardiovascular and infectious diseases - therapeutic areas that are now accounting for 70 per cent of all new drugs.

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.